Conducting clinical and field trials in the UK for innovative drugs can be a mine field due to the risk of infringing third party patents through the use of patented drugs in the trials or because the
Conducting clinical and field trials in the UK for innovative drugs can be a mine field due to the risk of infringing third party patents through the use of patented drugs in the trials or because the innovative drug infringes such patents. The UK Government announced at the end of February that it supports amending the Patents Act 1977 to remove this uncertainty and make the UK a more attractive place to conduct clinical and field trials.
Please see our full article on this topic that first appeared in Scrip Regulatory Affairs on 1 April 2013.
Conducting clinical and field trials in the UK for innovative drugs can be a mine field due to the risk of infringing third party patents through the use of patented drugs in the trials or because the innovative drug infringes such patents. The UK Government announced at the end of February that it supports amending the Patents Act 1977 to remove this uncertainty and make the UK a more attractive place to conduct clinical and field trials.
Please see our full article on this topic that first appeared in Scrip Regulatory Affairs on 1 April 2013.